Home »
Academic Articles »
C »
Health claims about cannabidiol (CBD) at the point-of-sale in three U.S. states with disparate cannabis policies
Health claims about cannabidiol (CBD) at the point-of-sale in three U.S. states with disparate cannabis policies
Kimberly G. Wagoner
(Department of Social Sciences and Health Policy, Wake Forest University School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157, USA; Corresponding author.)
Olivia E. Horton
(Department of Social Sciences and Health Policy, Wake Forest University School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157, USA)
Cynthia K. Suerken
(Department of Biostatistics and Data Science, Wake Forest University School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157, USA)
E. Alfonso Romero-Sandoval
(Department of Anesthesiology, Wake Forest University School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157, USA)
Allison J. Lazard
(Hussman School of Journalism and Media, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA)
Kerry Cork
(Public Health Law Center, Mitchell Hamline School of Law, Saint Paul, MN 55104, USA)
Renee Parker
(Department of Anesthesiology, Wake Forest University School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157, USA)
Beth A. Reboussin
(Department of Biostatistics and Data Science, Wake Forest University School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157, USA)
Journal: Preventive Medicine Reports
•
• Elsevier
• ISSN: 2211-3355
Abstract
Objectives: We assessed point-of-sale advertising for CBD in three states with different cannabis laws (i.e., medical/recreational use; medical only; CBD/low THC) to determine if CBD is marketed in ways that are prohibited by the U.S. Food and Drug Administration (FDA). Under FDA authority, CBD cannot be marketed with misleading advertising, as an unapproved drug, dietary supplement, food product, or FDA-approved/endorsed product. Methods: Between November 2021 and April 2022, two trained data collectors systematically documented point-of-sale advertising in 150 retailers using wearable imaging in Colorado, Maryland, and North Carolina. Advertising was content analyzed to determine the types of cannabinoids, prohibited health claims, and medical conditions it claimed to affect. Results: We documented and content analyzed 1090 CBD-specific advertisements, resulting in 985 prohibited claims, representing all claim types. Among CBD-specific ads, over half (61.8%) contained at least one prohibited claim. CBD was frequently advertised as an unapproved drug (53.6%) and food additive (51.6%). Prohibited therapeutic claims were made for 125 different health conditions, including pain, inflammation, and cancer. Most retailers (80%) displayed at least one prohibited claim. Conclusions: Prohibited advertising for CBD, which may mislead consumers about its risks and benefits, is extensive at the point-of-sale, highlighting the need for enforcement efforts.
Kimberly G. Wagoner, Olivia E. Horton, Cynthia K. Suerken, et al. (2026). "Health claims about cannabidiol (CBD) at the point-of-sale in three U.S. states with disparate cannabis policies". Preventive Medicine Reports. https://doi.org/10.1016/j.pmedr.2026.103472